Global Pediatric Palliative Care Drugs Market - Regional Analysis
Among region, North America is estimated to hold a dominant position in the global pediatric palliative care drugs market over the forecast period owing to increasing launches of products. For instance, on September 12, 2022, the U.S. FDA announced the approval of Atezolizumab [Tecentriq], as a single agent, for the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS). The approval was given to Genentech, Inc., a U.S.-based biotechnology corporation.
Pediatric Palliative Care Drugs Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients